CH
LRMR icon

CVI Holdings’s Larimar Therapeutics LRMR Stock Holding History

CVI Holdings’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-142,274
Closed -$588K – 433
2022
Q4 		$588K Sell
142,274
-401,410
-74% -$1.37M 0.07% 226
2022
Q3 		$1.74M Buy
+543,684
New +$1.36M 0.13% 253

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

CVI Holdings's LRMR Position: Q1 2023 in Review

CVI Holdings sold out of Larimar Therapeutics (LRMR) in Q1 2023, closing a stake of 142,274 shares — an estimated $588K sold.

CVI Holdings first reported a position in LRMR in Q3 2022 and held it in 2 quarters. The position peaked at $1.74M in Q3 2022. 68 funds tracked by Wall St. Rank hold LRMR as of Q1 2023.

  • CVI Holdings reported no remaining Larimar Therapeutics position as of Q1 2023 after selling out during the quarter.
  • CVI Holdings sold 142,274 Larimar Therapeutics shares in Q1 2023, an estimated $588K.
  • CVI Holdings first reported a position in Larimar Therapeutics in Q3 2022 and held it in 2 quarters.
  • CVI Holdings's Larimar Therapeutics position peaked at $1.74M in Q3 2022.
  • 68 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2023.

Based on CVI Holdings's 13F filing for Q1 2023, filed 16 May 2023.